US Patent Issued to Ultragenyx Pharmaceutical on July 21 for "Gene therapy for treating propionic acidemia" (Massachusetts, Ohio, California Inventors)

ALEXANDRIA, Va., July 21 -- United States Patent no. 12,686,874, issued on July 21, was assigned to Ultragenyx Pharmaceutical Inc. (Novato, Calif.).

"Gene therapy for treating propionic acidemia" was invented by Matthew Scott Fuller (Millis, Mass.), Samuel Wadsworth (Monterey, Mass.), Kelly Reed Clark (Westerville, Ohio), Sean Christopher Daugherty (Petaluma, Calif.) and Stewart Craig (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "This present disclosure provides recombinant adeno-associated virus (rAAV) and methods of their use in gene therapy for treating propionic acidemia (PA). Also provided are pharmaceutical compositions comprising a rAAV of the invention and a pharmaceutically accept...